Loading
Ferroptosis and Cancer Prognosis · Journal article
Journal of Nanobiotechnology · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This preclinical study presents a novel radioactive copper nanoparticle (ES-64Cu@NP-RGD) that accumulates in glioblastoma xenografts and upregulates cuproptosis pathways in vitro and in vivo, extending median survival to 36 days in untreated murine controls. The mechanism is mechanistically interesting but remains unvalidated in human disease and lacks independent verification or head-to-head comparison with standard of care.
Preclinical in vivo glioblastoma xenograft study. U87-MG human glioblastoma cell line-derived xenografts in mice; no patient data or human enrollment.. Intervention: ES-64Cu@NP-RGD: radioactive copper (64Cu) complexed with elesclomol and delivered via RGD-modified nanoparticles..
High tumor accumulation of 7.66 ± 0.93 %ID/g in U87-MG xenografts at 4 hours by PET imaging Upregulation of cuproptosis proteins FDX1 and DLAT, accompanied by increased γ-H2AX (DNA damage) and oxidative stress Median survival extended to 36 days in murine models with ES-64Cu@NP treatment, without observable systemic toxicity
Median survival extended to 36 days in murine models with ES-64Cu@NP treatment, without observable systemic toxicity
This work is exploratory mechanistic evidence in animals and does not yet support clinical use. Clinicians should view this as hypothesis-generating research requiring substantial further validation, including independent replication, safety profiling, and eventual human trials before any therapeutic application.
This is a preclinical mechanistic study in murine glioblastoma models demonstrating a novel theranostic approach; it lacks human data, control comparators, and independent replication needed for clinical translation.
As stated by the source record.
Quoted from the source exactly as published.
This work is exploratory mechanistic evidence in animals and does not yet support clinical use. Clinicians should view this as hypothesis-generating research requiring substantial further validation, including independent replication, safety profiling, and eventual human trials before any therapeutic application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Cuproptosis, a unique form of programmed cell death triggered by copper overload and subsequent proteotoxic stress, represents a promising avenue for cancer therapy. Radiotherapy may influence cuproptosis-related pathways in tumors, highlighting the possibility of combining radiotherapy to enhance cuproptosisis. However, how copper delivered in a radioactive form affects these processes remains unclear. Here, we doped radioactive 64 Cu into elesclomol (ES-Cu[II]) and encapsulated by an RGD-modified nanoparticle, named ES- 64 Cu[II] @Nanoparticle-RGD (ES- 64 Cu@NP). This agent demonstrated high tumor accumulation (7.66 ± 0.93 %ID/g in U87-MG tumors at 4 h) via PET imaging. The internal irradiation from 64 Cu upregulated key cuproptosis proteins (FDX1, DLAT), accompanied by increased DNA damage signaling (γ-H2AX) and oxidative stress. This dual-sensitization mechanism resulted in synergistic antitumor efficacy, significantly inhibiting glioblastoma growth and extending median survival to 36 days in murine models, without observable systemic toxicity. These findings indicate that radioactive copper delivery can modulate cuproptosis-associated signaling while enabling PET-guided tracking, supporting this theranostic strategy for investigating copper-dependent stress responses in cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.